Skip to main content
SpringerLink
Log in

Psychopharmaka

  • Chapter
Arzneiverordnungs-Report 2013

  • 1787 Accesses

Zusammenfassung

Die Psychopharmaka lassen sich in fünf Gruppen unterteilen: Antidepressiva, Neuroleptika, Tranquillantien (ganz überwiegend Benzodiazepine) und Psychostimulanzien sowie pflanzliche Psychopharmaka (überwiegend Johanniskrautextrakte).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 49.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Allroggen M, Udvardi PT, Pleuer PL, Kölch M, Fegert J M, Ludolph AG (2010): Langzeiteffekte von Psychostimulanzien – Welche Auswirkungen sind uns aus prä-/klinischen Studien bekannt. Psychopharmakotherapie 17: 125–131.

    Google Scholar 

  • American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity (2004): Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 27: 596–601.

    Google Scholar 

  • Anderson IM (2000): Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. J Affect Disord 58: 19–36.

    Article  PubMed  CAS  Google Scholar 

  • Anonym (2003): Lithium-Therapie bei der manisch-depressiven Erkrankung: Immer noch der Standard? Arzneimittelbrief 37: 49–51.

    Google Scholar 

  • Anonym (2005): Aripiprazole. Prescrire International 14: 163.

    Google Scholar 

  • Anonym (2008): Kinder: Neuroleptikagebrauch steigt. Arzneitelegramm 39: 69–70.

    Google Scholar 

  • Anonym (2009): Psychopanacea? Prescrire Internat 18: 53.

    Google Scholar 

  • Anonym (2010): Big Pharma unbelehrbar? Strafen für illegales Marketing zu lasch. Pharmabrief Nr.10: 6–7.

    Google Scholar 

  • Anonym (2011a): Monitoring unwanted effects of antispychotics. Drug Ther Bull 49: 117–120.

    Google Scholar 

  • Anonym (2013): Agomelatine: A review of its adverse effects. Prescrire Int 22: 70–71.

    Google Scholar 

  • Arroll B, Macgillivray S, Ogston S, Reid I, Sullivan F, Williams B, Crombie I (2005): Efficacy and tolerability of tricyclic antidepressants and SSRIs compared with placebo for treatment of depression in primary care: a meta-analysis. Ann Fam Med 3: 449–456.

    Article  PubMed  Google Scholar 

  • Arzneimittelkommission der deutschen Ärzteschaft (2004) : Suizide und Suizidversuche unter Bupropion. Deutsches Ärzteblatt 101 : A 2139–2140

    Google Scholar 

  • Arzneimittelkommission der deutschen Ärzteschaft (2006): Hypersexualität unter Aripiprazol. Deutsches Ärzteblatt 103: A3518.

    Google Scholar 

  • Arzneimittelkommission der deutschen Ärzteschaft (2008): Stellenwert von Antidepressiva in der Depressionsbehandlung. Arzneiverordnung in der Praxis 35: 42–43.

    Google Scholar 

  • Arzneimittelkommission der deutschen Ärzteschaft (Hrsg) (2009): Arzneiverordnungen. 22. Auflage, Medizinische Medien Informations GmbH (MMI), Neu-Isenburg.

    Google Scholar 

  • Baandrup L, Gasse C, Jensen VD, Glenthoj BY, Nordentoft M, Lublin H, Fink-Jensen A, Lindhardt A, Mortensen PB (2010): Antipsychotic polypharmacy and risk of death from natural causes in patients with schizophrenia: a population-based nested casecontrol study. J Clin Psychiatry 71: 103–108.

    Google Scholar 

  • Baghai TC, Lieb M, Möller HJ, Bschor T, Härter M, Schauenburg H.(2011): Antidepressiva bei leichten depressiven Störungen. Psychiatr Prax 38: 270–273.

    Article  PubMed  Google Scholar 

  • Bauer M, Adli M, Bschor T, Pilhatsch M, Pfennig A, Sasse J, Schmid R, Lewitzka U (2010): Lithium’s emerging role in the treatment of refractory major depressive episodes: augmentation of antidepressants. Neuropsychobiology 62: 36–42

    Article  PubMed  CAS  Google Scholar 

  • Bauer M, Grof P, Müller-Oerlinghausen B (Hsgb.) (2006): Lithium in Neuropsychiatry: The Comprehensive Guide. Informa healthcare. Oxon (UK)

    Google Scholar 

  • Bschor T, Adli M (2009): Therapie depressiver Erkrankungen. Dtsch Ärztebl 105: A 782– A 792.

    Google Scholar 

  • Bschor T, Hartung HD (2008): Antidepressiva Kombinationsbehandlungen. In Bschor T (Hsgb): Behandlungsmanual therapieresistenter Depressiononen. Kohlhammer, Stuttgart, S. 86–101.

    Google Scholar 

  • Carlson GA, Potegal M, Margulies D, Basile J, Gutkovich Z (2010): Liquid risperidone in the treatment of rages in psychiatrically hospitalized children with possible bipolar disorder. Bipolar Disord 12: 205–212.

    Article  PubMed  Google Scholar 

  • Carter NJ (2012): Extended-Release Intramuscular Paliperidone Palmitate: A Review of its Use in the Treatment of Schizophrenia. Drugs 72: 1137–1160.

    Article  PubMed  CAS  Google Scholar 

  • Cipriani A, Furukawa TA, Salanti G, Geddes JR, Higgins JP, Churchill R, Watanabe N, Nakagawa A, Omori IM, McGuire H, Tansella M, Barbui C (2009): Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet 373: 746–758.

    Article  PubMed  CAS  Google Scholar 

  • Cipriani A, Pretty H, Hawton K, Geddes JR (2005): Lithium in the prevention of suicidal behavior and all-cause mortality in patients with mood disorders: a systematic review of randomized trials. Am J Psychiatry 162: 1805–1819.

    Article  PubMed  Google Scholar 

  • Cipriani A, Rendell J, Geddes JR (2010) : Olanzapine in the long-term treatment of bipolar disorder: a systematic review and meta-analysis. J Psychopharmacol 24: 1729–1738.

    Article  PubMed  CAS  Google Scholar 

  • Clark RE, Bartels SJ, Mellman TA, Peacock WJ (2002): Recent trends in antipsychotic combination therapy of schizophrenia and schizoaffective disorder: implications for state mental health policy. Schizophr Bull 28: 75–84.

    Article  PubMed  Google Scholar 

  • Collins JC, McFarland BH (2008): Divalproex, lithium and suicide among Medicaid patients with bipolar disorder .J Affect Disord 107: 23–28.

    Article  PubMed  CAS  Google Scholar 

  • Connolly KR, Thase ME (2011): If at first you don’t succeed: a review of the evidence for antidepressant augmentation, combination and switching strategies. Drugs 71: 43–64.

    Article  PubMed  CAS  Google Scholar 

  • Cooper WO, Habel LA, Sox CM, Chan KA, Arbogast PG, Cheetham TC, Murray KT, Quinn VP, Stein CM, Callahan ST, Fireman BH, Fish FA, Kirshner HS, O’Duffy A, Connell FA, Ray WA (2011): ADHD drugs and serious cardiovascular events in children and young adults. N Engl J Med 365: 1896–1904.

    Article  PubMed  CAS  Google Scholar 

  • Coupland C, Dhiman P, Morriss R, Arthur A, Barton G, Hippisley-Cox J (2011): Antidepressant use and risk of adverse outcomes in older people: population based cohort study. BMJ 343: d4551. doi: 10.1136/bmj.d4551.

    Google Scholar 

  • Croissant B, Mann K (2004): Pharmakologische Rückfallprophylaxe bei Alkoholabhängigkeit. Psychoneuro 30: 30–36.

    Article  Google Scholar 

  • Davidson M, Galderisi S, Weiser M, Werbeloff N, Fleischhacker WW, Keefe RS, Boter H, Keet IP, Prelipceanu D, Rybakowski JK, Libiger J, Hummer M, Dollfus S, López- Ibor JJ, Hranov LG, Gaebel W, Peuskens J, Lindefors N, Riecher-Rössler A, Kahn RS (2009): Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-label clinical trial (EUFEST). Am J Psychiatry 166: 675–682.

    Article  PubMed  Google Scholar 

  • Dersch R, Zwernemann S, Voderholzer U (2011): Partial status epilepticus after electroconvulsive therapy and medical treatment with bupropion. Pharmacopsychiatry 44: 344–346.

    Article  PubMed  CAS  Google Scholar 

  • Deutsche Gesellschaft für Bipolare Störungen (2006) : Weissbuch Bipolare Störungen in Deutschland. www.dgbs.de

  • Deutsche Gesellschaft für Psychiatrie, Psychotherapie und Nervenheilkunde (DGPPN) (2009): S3-Leitlinie/Nationale VersorgungsLeitlinie Unipolare Depression. Internet: media.dgppn.de/mediadb/media/dgppn/pdf/leitlinien/s3-nvl-unipolare-depressionlf. pdf

    Google Scholar 

  • Deutsche Gesellschaft für Soziale Psychiatrie (DGSP) (2009): DGSP-Memorandum zur Anwendung von Antipsychotika. Soziale Psychiatrie 34: 50–51.

    Google Scholar 

  • De Zwaan M, Gruss B, Müller A, Graap H, Martin A, Glaesmer H, Hilbert A, Philipsen A (2012): The estimated prevalence and correlates of adult ADHD in a German community sample. Eur Arch Psychiatry Clin Neurosci 262: 79–86.

    Article  PubMed  Google Scholar 

  • Dolder CR, Nelson M, Snider M (2008): Agomelatine treatment of major depressive disorder. Ann Pharmacother 42: 1822–1831.

    Article  PubMed  CAS  Google Scholar 

  • Ernst CL, Goldberg JF (2004): Antisuicide properties of psychotropic drugs: a critical review. Harv Rev Psychiatry 12: 14–41.

    PubMed  Google Scholar 

  • European Medicines Agency (2010): Questions and answers on the review of medicines containing valproate for use in bipolar disorder. Internet: www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/valproate_31/WC500042697.pdf

  • European Medicines Agency (2011): Fragen und Antworten zu der Überprüfung von Modafinil-haltigen Arzneimitteln. Einschränkung der Indikationen nach einem Prüfungsverfahren gemäß Artikel 31 der Richtlinie 2001/83/EG in der geltenden Fassung. Internet: www.emea.europa.eu/docs/de_DE/document_library/Referrals_document/Modafinil_31/WC500099177.pdf

  • Food and Drug Administration (FDA) (2007): FDA proposes new warnings about suicidal thinking, behaviour in young adults to take antidepressant medications. www.fda.gov/bbs/topics/NEWS/2007/NEW01624.html.

  • Fountoulakis KN, Möller HJ (2010): Efficacy of antidepressants: a re-analysis and re-interpretation of the Kirsch data. Int J Neuropsychopharmacol 14 : 405–412.

    Article  PubMed  CAS  Google Scholar 

  • Friedmann PD (2013): Alcohol use in adults. N Engl J Med 368: 1655–1656.

    Article  PubMed  CAS  Google Scholar 

  • Frye MA, Ketter TA, Leverich GS, Huggins T, Lantz C, Denicoff KD, Post RM (2000): The increasing use of polypharmacotherapy for refractory mood disorders: 22 years of study. J Clin Psychiatry 61: 9–15.

    Article  PubMed  CAS  Google Scholar 

  • Gaebel W, Riesbeck M, Wölwer W, Klimke A, Eickhoff M, von Wilmsdorff M, Jockers- Scherübl MC, Kühn KU, Lemke M, Bechdolf A, Bender S, Degner D, Schlösser R, Schmidt LG, Schmitt A, Jäger M, Buchkremer G, Falkai P, Klingberg S, Köpcke W, Maier W, Häfner H, Ohmann C, Salize HJ, Schneider F, Möller HJ; German Study Group on First-Episode Schizophrenia (2007): Maintenance treatment with risperidone or low-dose haloperidol in first-episode schizophrenia: 1-year results of a randomized controlled trial within the German Research Network on Schizophrenia. J Clin Psychiatry 68: 1763–1774.

    Google Scholar 

  • Gartlehner G, Gaynes BN, Hansen RA, Thieda P, DeVeaugh-Geiss A, Krebs EE, Moore CG, Morgan L, Lohr KN (2008): Comparative benefits and harms of second-generation antidepressants: Background paper for the American College of Physicians. Ann Int Med 149: 734–750.

    Article  PubMed  Google Scholar 

  • Geddes J, Freemantle N, Harrison P, Bebbington P (2000): Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. Brit Med J 321: 1371–1376.

    Article  PubMed  CAS  Google Scholar 

  • Geddes JR, Freemantle N, Mason J, Eccles MP, Boynton J (2001): SSRIs versus other antidepressants for depressive disorder. Update Software Ltd Oxford, The Cochrane Library – Issue 1.

    Google Scholar 

  • Gemeinsamer Bundesausschuss (2010): Bekanntmachung eines Beschlusses des Gemeinsamen Bundesausschusses über eine Änderung der Arzneimittel-Richtlinie: Anlage III Nummer 44 Stimulantien Vom 16. September 2010. Internet: www.g-ba.de/downloads/39-261-1185/2010-09-16_AM-RL3_Stimulantien_BAnz.pdf

  • Gentile S (2007): Atypical antipsychotics for the treatment of bipolar disorders. CNS Drugs 21: 367–387.

    Article  PubMed  CAS  Google Scholar 

  • Gibbons RD, Brown CH, Hur K, Marcus SM, Baumikh DK, Erkenmann JJ (2007): Early evidence on the effects of regulators’ suicidality warnings on prescriptions and suicide in children and adolescents. Am J Psychiatry 164: 1356–1363.

    Article  PubMed  Google Scholar 

  • Goldberg TE, Gomar JJ (2009): Targeting cognition in schizophrenia research: from etiology to treatment. Am J Psychiatry 166: 631–634.

    Article  PubMed  Google Scholar 

  • Gonzalez-Pinto A, Mosquera F, Alonso M, López P, Ramírez F, Vieta E, Baldessarini RJ (2006): Suicidal risk in bipolar I disorder patients and adherence to long-term lithium treatment. Bipolar Disord 8: 618–24

    Article  PubMed  CAS  Google Scholar 

  • Goodwin FK, Fireman B, Simon GE, Hunkeler EM, Lee J, Revicki D (2003): Suicide risk in bipolar disorder during treatment with lithium and divalproex. JAMA 290: 1467– 1473.

    Article  PubMed  CAS  Google Scholar 

  • Goodwin GM, Bowden CL, Calabrese JR, Grunze H, Kasper S, White R, Greene P, Leadbetter R (2004): A pooled analysis of 2 placebo-controlled 18-month trials of lamotrigine and lithium maintenance in bipolar I disorder. J Clin Psychiatry 65: 432–441.

    Article  PubMed  CAS  Google Scholar 

  • Gould MS, Walsh BT, Munfakh JL, Kleinman M, Duan N, Olfson M, Greenhill L, Cooper T (2009): Sudden death and use of stimulant medications in youths. Am J Psychiatry 166: 992–1001.

    Article  PubMed  Google Scholar 

  • Greil W, Häberle A, Haueis P, Grohmann R, Russmann S (2012): Pharmacotherapeutic trends in 2231 psychiatric inpatients with bipolar depression from the International AMSP Project between 1994 and 2009. Affect Disord 136: 534–1542.

    Article  Google Scholar 

  • Greil W, Ludwig-Mayerhofer W, Erazo N, Engel RR, Czernik A, Giedke H, Müller-Oerlinghausen B, Osterheider M, Rudolf GA, Sauer H, Tegeler J, Wetterling T (1996): Comparative efficacy of lithium and amitriptyline in the maintenance treatment of recurrent unipolar depression: a randomised study. J Affect Disord 40: 179–190.

    Article  PubMed  CAS  Google Scholar 

  • Grof P (2013): Melancholia: a distinct entity? Can J Psychiatry 58: 181–182.

    PubMed  Google Scholar 

  • Grof P, Müller-Oerlinghausen B (2009): A critical appraisal of lithium’s efficacy and effectiveness: the last 60 years. Bipolar Disord 11 (Suppl 2): 10–19.

    Article  PubMed  CAS  Google Scholar 

  • Grohmann R, Engel RR, Geissler KH, Rüther E (2004): Psychotropic drug use in psychiatric inpatients: recent trends and changes over time-data from the AMSP study. Pharmacopsychiatry 37 Suppl 1: S27–38.

    PubMed  Google Scholar 

  • Grund T, Lehmann K, Bock N, Rothenberger A, Teuchert-Noodt G (2006): Influence of methylphenidate on brain development – an update of recent animal experiments. Behav Brain Funct 10: 2.

    Article  CAS  Google Scholar 

  • Hach I, Rentsch A, Krappweis J, Kirch W (2004): Psychopharmakaverordnungen an älteren Patienten. Z Gerontol Geriatr 37: 214–220.

    Article  PubMed  CAS  Google Scholar 

  • Hägg S, Bate A, Stahl M, Spigset O (2008): Associations between venous thromboembolism and antipsychotics. A study of the WHO database of adverse drug reactions. Drug Saf 31: 685–694.

    Article  PubMed  Google Scholar 

  • Hansen R, Gaynes B, Thieda P, Gartlehner G, Deveaugh-Geiss A, Krebs E, Lohr K (2008): Meta-analysis of major depressive disorder relapse and recurrence with second-generation antidepressants. Psychiatr Serv 59: 1121–1130.

    Article  PubMed  Google Scholar 

  • Healy D (2003): Lines of evidence on the risks of suicide with selective serotonin reuptake inhibitors. Psychother Psychosom 72: 71–79.

    Article  PubMed  Google Scholar 

  • Healy D (2006a): The latest mania: selling bipolar disorders. PLoS Med 3: e185.

    Article  Google Scholar 

  • Healy (2006b): Did regulators fail over selective serotonin reuptake inhibitors? BMJ 333: 92–95.

    Google Scholar 

  • Hegerl U, Mergl R, Quail D, Schneider E, Hundemer HP, Linden M (2012): Does pain improve earlier than mood in depressed patients with painful physical symptoms treated with duloxetine? Pharmacopsychiatry 45: 114–118.

    Article  PubMed  CAS  Google Scholar 

  • Hjern A, Weitoft GR, Lindblad F (2010): Social adversity predicts ADHD-medication in school children--a national cohort study. Acta Paediatr 99: 920–924.

    Article  PubMed  CAS  Google Scholar 

  • Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IWiG) (2009): Selektive Serotonin- und Noradrenalin-Wiederaufnahmehemmer (SNRI) bei Patienten mit Depressionen. Abschlussbericht A05-20A. Stand 17.06.2009. Internet: www.iqwig.de/download/A05-20A_Abschlussbericht_SNRI_bei_Patienten_mit_Depressionen.pdf

  • Jans T, Warnke A (2010): Die britische NICE-Guidance zu Diagnose und Therapie der Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung (ADHS) im Kindes-, Jugend- und Erwachsenenalter. Arzneiverordnung in der Praxis. 37: 4–6.

    Google Scholar 

  • Jones PB, Barnes TR, Davies L, Dunn G, Lloyd H, Hayhurst KP, Murray RM, Markwick A, Lewis SW (2006): Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry 63: 1079–1087.

    Article  PubMed  CAS  Google Scholar 

  • Jureidini JN, Doecke CJ, Mansfield PR, Haby MM, Menkes DB, Tonkin AL (2004): Efficacy and safety of antidepressants for children and adolescents. BMJ 328: 879–883.

    Article  PubMed  CAS  Google Scholar 

  • Juurlink DN, Mamdani MM, Kopp A, Redelmeier DA (2006): The risk of suicide with selective serotonin reuptake inhibitors in the elderly. Am J Psychiatry 163: 813–821.

    Article  PubMed  Google Scholar 

  • Kahn RS, Fleischhacker WW, Boter H, Davidson M, Vergouwe Y, Keet IP, Gheorghe MD, Rybakowski JK, Galderisi S, Libiger J, Hummer M, Dollfus S, López-Ibor JJ, Hranov LG, Gaebel W, Peuskens J, Lindefors N, Riecher-Rössler A, Grobbee DE; EUFEST study group (2008): Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 371: 1085–1097.

    Google Scholar 

  • Kane J, Honigfeld G, Singer J, Meltzer H (1988): Clozapine for the treatment-resistant schizophrenic. Arch Gen Psychiatry 45: 789–796.

    Article  PubMed  CAS  Google Scholar 

  • Kasper S, Caraci F, Forti B, Drago F, Aguglia E (2010): Efficacy and tolerability of Hypericum extract for the treatment of mild to moderate depression. Eur Neuropsychopharmacol 20: 747–765.

    Article  PubMed  CAS  Google Scholar 

  • Kassenärztliche Bundesvereinigung (2006): Wirkstoff aktuell: Quetiapin (SeroquelÒ). Ausgabe 05/2006. Internet: www.akdae.de/Arzneimitteltherapie/WA/Archiv/Quetiapin.pdf

  • Kassenärztliche Bundesvereinigung (2008): Wirkstoff aktuell: Venlafaxin (TrevilorÒ). Ausgabe 03/2008. Internet: www.akdae.de/Arzneimitteltherapie/WA/Archiv/Venlafaxin.pdf

  • Kassenärztliche Bundesvereinigung (2010a: Wirkstoff Aktuell: Aripiprazol (Abilify®). Ausgabe 03/2010. Internet: www.akdae.de/Arzneimitteltherapie/WA/Archiv/Aripiprazol.pdf

  • Kassenärztliche Bundesvereinigung (2010b: Agomelatin. Wirkstoff aktuell, Ausgabe 05/2010 Internet: www.akdae.de/Arzneimitteltherapie/WA/Archiv/Agomelatin.pdf

  • Kendrick T, Chatwin J, Dowrick C, Tylee A, Morriss R, Peveler R, Leese M, McCrone P, Harris T, Moore M, Byng R, Brown G, Barthel S, Mander H, Ring A, Kelly V, Wallace V, Gabbay M, Craig T, Mann A (2009): Randomised controlled trial to determine the clinical effectiveness and cost-effectiveness of selective serotonin reuptake inhibitors plus supportive care, versus supportive care alone, for mild to moderate depression with somatic symptoms in primary care: the THREAD (THREshold for AntiDepressant response) study. Health Technol Assess 13: iii–iv, ix–xi, 1–159.

    Google Scholar 

  • Kessler RC, Demler O, Frank RG, Olfson M, Pincus HA, Walters EE, Wang P, Wells KB, Zaslavsky AM (2005): Prevalence and treatment of mental disorders, 1990 to 2003. N Engl J Med 352: 2515–2523.

    Article  PubMed  CAS  Google Scholar 

  • Kirsch I, Deacon BJ, Huedo-Medina TB, Scoboria A, Moore TJ, Johnson BT (2008): Initial severity and antidepressant benefit: a meta-analysis of data submitted to the Food and Drug Administration. PloS Med 5: e45.

    Article  PubMed  Google Scholar 

  • Komossa K, Depping AM, Meyer M, Kissling W, Leucht S (2010): Second-generation antipsychotics for obsessive compulsive disorder. Cochrane Database Syst Rev. 2010 Dec 8; (12): CD008141.

    Google Scholar 

  • Komossa K, Rummel-Kluge C, Schmid F, Hunger H, Schwarz S, El-Sayeh HG, Kissling W, Leucht S (2009): Aripiprazole versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2009 Oct 7; (4): CD006569.

    Google Scholar 

  • Konstantinidis A, Papageorgiou K, Grohmann R, Horvath A, Engel R, Kasper S (2012): Increase of antipsychotic medication in depressive inpatients from 2000 to 2007: results from the AMSP International Pharmacovigilance Program. Int J Neuropsychopharmacol 15: 449–457.

    Article  PubMed  CAS  Google Scholar 

  • Kupfer DJ, Frank E, Phillips ML (2012): Major depressive disorder: new clinical, neurobiological, and treatment perspectives. Lancet 379: 1045–1055.

    Article  PubMed  Google Scholar 

  • Landessozialgericht Berlin-Brandenburg (2011): Beschluss vom 6. Dezember 2011 in dem Rechtsstreit Lundbeck GmbH – Antragstellerin – gegen Spitzenverband Bund der Krankenkassen – Antragsgegnerin – Gemeinsamer Bundesausschuss, Unterausschuss „Arzneimittel“ – Beigeladener (Az.: L 1 KR 184/11 ER).

    Google Scholar 

  • Lesch OM, Riegler A, Gutierrez K, Hertling I, Ramskogler K, Semler B, Zoghlami A, Benda N, Walter H (2001): The European acamprosate trials. Conclusions for research and therapy. J Biomed Sci 8: 89–95.

    Article  PubMed  CAS  Google Scholar 

  • Letmaier M, Painold A, Holl AK, Vergin H, Engel R, Konstantinidis A, Kasper S, Grohmann R (2011): Hyponatraemia during psychopharmacological treatment: results of a drug surveillance programme. Int J Neuropsychopharmacol 22: 1–10.

    Google Scholar 

  • Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM (2009): Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 373: 31–41.

    Article  PubMed  CAS  Google Scholar 

  • Leucht S, Wahlbeck K, Hamann J, Kissling W (2003): New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet 361: 1581–1589.

    Article  PubMed  CAS  Google Scholar 

  • Lewitzka U, Bauer M, Felber W, Müller-Oerlinghausen B (2013): Suizidprophylaktische Wirkung von Lithium. Aktueller Forschungsstand und Implikationen für die Therapie affektiver Störungen Nervenarzt 84: 294–306.

    CAS  Google Scholar 

  • Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK; Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators (2005): Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353: 1209–1233.

    Google Scholar 

  • Linde K, Berner M, Egger M, Mulrow C (2005): St John‘s wort for depression: meta-analysis of randomised controlled trials. Br J Psychiatry 186: 99–107.

    Article  PubMed  Google Scholar 

  • MacGillivray S, Arroll B, Hatcher S, Ogston S, Reid I, Sullivan F, Williams B, Crombie I (2003): Efficacy and tolerability of selective serotonin reuptake inhibitors compared with tricyclic antidepressants in depression treated in primary care: systematic review and meta-analysis. Brit Med J 326: 1014–1019.

    Article  PubMed  CAS  Google Scholar 

  • Macritchie KAN, Geddes MR, Scott J, Haslam DRS, Goodwin GM (2001): Valproic acid, valproate and divalproex in the maintenance treatment of bipolar disorders. Cochrane Review. In: The Cochrane Library Issue 3. Oxford, Updated Software.

    Google Scholar 

  • Maher AR, Maglione M, Bagley S, Suttorp M, Hu JH, Ewing B, Wang Z, Timmer M, Sultzer D, Shekelle PG (2011): Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: a systematic review and meta-analysis. JAMA 306: 1359–1369.

    Article  PubMed  CAS  Google Scholar 

  • Maher AR, Theodore G (2012): Summary of the comparative effectiveness review on offlabel use of atypical antipsychotics. J Manag Care Pharm 18 (5 Suppl B): S1–20.

    PubMed  Google Scholar 

  • McDonagh M, Peterson K, Carson S, Fu R, Thakurta S (2010): Drug Class Review: Atypical Antipsychotic Drugs. Final Update 3 Report. Portland (OR): Oregon Health & Science University; July 2010. Internet: www.ncbi.nlm.nih.gov/books/NBK50583/

  • McEvoy JP, Lieberman JA, Stroup TS, Davis SM, Meltzer HY, Rosenheck RA, Swartz MS, Perkins DO, Keefe RS, Davis CE, Severe J, Hsiao JK; CATIE Investigators (2006): Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry 163: 600–610.

    Google Scholar 

  • McKnight RF, Adida M, Budge K, Stockton S, Goodwin GM, Geddes JR (2012): Lithium toxicity profile: a systematic review and meta-analysis. Lancet 379: 721–728.

    Article  PubMed  CAS  Google Scholar 

  • Mészáros A, Czobor P, Bálint S, Komlósi S, Simon V, Bitter I (2009): Pharmacotherapy of adult attention deficit hyperactivity disorder (ADHD): a meta-analysis. Int J Neuropsychopharmacol 12: 1137–1147.

    Article  PubMed  CAS  Google Scholar 

  • Mitchell AJ, Vaze A, Rao S (2009): Clinical diagnosis of depression in primary care: a meta-analysis. Lancet 374: 609–619.

    Article  PubMed  Google Scholar 

  • Miyamoto S,Miyake S,Jarskog LF,Fleischhacker WW, Lieberman JA (2012) Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents. Mol Psychiatry 17: 1206–1227

    Article  PubMed  CAS  Google Scholar 

  • Molina BSG, Florey K, Hinshaw SP, Greiner, AR, Arnold E, Swanson JM, Hechtman L, Jensen PS, Vitiello B, Hoza B, Pelham WE, Elliot GR, Wells KC, Abikoff HB, Gibbons RD, Marcus S, Conners CK, Epstein JN, Greenhill LL, March JS, Newcorn JH, Severe JB, Wigal T (2007): Delinquent behavior and emerging substance use in the MTA at 36 months: Prevalence, course, and treatment effects. J Am Acad Child Adolesc Psychiatry 46: 1028–1040.

    Article  PubMed  Google Scholar 

  • Möller H-J, Volz HP, Reimann IW, Stoll KD (2001): Opipramol for the treatment of generalized anxiety disorder: a placebo-controlled trial including an alprazolam-treated group. J Clin Psychopharmacol 21: 59–65.

    Article  PubMed  Google Scholar 

  • Moncrieff J (2008): Steht die Psychiatrie zum Verkauf an? Sozialpsychiatr Informationen 38: 8–18.

    Google Scholar 

  • Moncrieff J, Kirsch I (2005): Efficacy of antidepressants in adults. BMJ 331: 155–157.

    Article  PubMed  Google Scholar 

  • Montgomery S, Hansen T, Kasper S (2011): Efficacy of escitalopram compared to citalopram: a meta-analysis. Int J Neuropsychopharmacol 14: 261–268.

    Article  PubMed  CAS  Google Scholar 

  • Moreno C, Laje G, Blanco C, Jiang H, Schmidt AB, Olfron M (2007): National trends in the outpatient diagnosis and treatment of bipolar disorders in youths. Arch Gen Psychiatry 64: 1032–1039.

    Article  PubMed  Google Scholar 

  • Moret C, Isaac M, Briley M (2009): Problems associated with long-term treatment with selective serotonin reuptake inhibitors. J Psychopharmacol 23: 967–974.

    Article  PubMed  CAS  Google Scholar 

  • MTA Cooperative Group (1999): A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Arch Gen Psychiat 56: 1073– 1086.

    Google Scholar 

  • Müller-Oerlinghausen B (2011): Antidepressiva sind nur bei sehr schwerer Depression Placebo überlegen. Arzneiverordnung in der Praxis 39: 60–62.

    Google Scholar 

  • National Institute of Health and Clinical Excellence (NICE) (2009): Schizophrenia. Core interventions in the treatment and management of schizophrenia in primary and secondary care (update). National Clinical Practice Guideline Number 82 (March 2009). Internet: www.nice.org.uk/nicemedia/pdf/CG82FullGuideline.pdf

  • Offidani E, Fava GA, Tomba E, Baldessarini RJ (2013): Excessive mood elevation and behavioral activation with antidepressant treatment of juvenile depressive and anxiety disorders: a systematic review. Psychother Psychosom 82: 132–141.

    Article  PubMed  Google Scholar 

  • Patel JK, Buckley PF, Woolson S, Hamer RM, McEvoy JP, Perkins DO, Lieberman JA, For The Cafe Investigators (2009): Metabolic profiles of second-generation antipsychotics in early psychosis: Findings from the CAFE study. Schizophr Res 111: 9–16.

    Google Scholar 

  • Pollock B, Forsyth C, Bies R (2009): The critical role of clinical pharmacology in geriatric psychopharmacology. Clin Pharmacol Ther 85: 89–93.

    Article  PubMed  Google Scholar 

  • Qaseem A, Snow V, Denberg TD, Forciea MA, Owens DK; Clinical Efficacy Assessment Subcommittee of American College of Physicians (2008): Using second-generation antidepressants to treat depressive disorders: a clinical practice guideline from the American College of Physicians. Ann Intern Med 149: 725–733.

    Google Scholar 

  • Rani F, Murray ML, Byrne PJ, Wong IC (2008): Epidemiologic features of antipsychotic prescribing to children and adolescents in primary care in the United Kingdom. Pediatrics 121: 1002–1009.

    Article  PubMed  Google Scholar 

  • Ray WA, Chung CP, Murray KT, Hall K, Stein CM (2009): Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med 360: 225–235.

    Article  PubMed  CAS  Google Scholar 

  • Reeves RR, Ladner ME (2010): Antidepressant-induced suicidality: an update. CNS Neurosci Ther 16: 227–234.

    PubMed  Google Scholar 

  • Remschmidt H, Global ADHD Working Group (2005): Global consensus on ADHD/ HKD. Eur Child Adolesc Psychiatry 14: 127–137.

    Google Scholar 

  • Robert Koch Institut (2008): Lebensphasenspezifische Gesundheit von Kindernund Jugendlichen in Deutschland. Beiträge zur Gesundheitsberichterstattung des Bundes. Robert Koch Institut, Berlin, Seite 1-179. Internet: www.rki.de/DE/Content/GBE/Gesundheitsberichterstattung/GBEDownloadsB/KiGGS__SVR,templateId=raw,property=publicationFile.pdf/KiGGS_SVR.pdf

  • Rosenberg PB, Drye LT, Martin BK, Frangakis C, Mintzer JE, Weintraub D, Porsteinsson AP, Schneider LS, Rabins PV, Munro CA, Meinert CL, Lyketsos CG; DIADS-2 Research Group (2010): Sertraline for the treatment of depression in Alzheimer disease. Am J Geriatr Psychiatry 18: 136–145.

    Google Scholar 

  • Rösner S, Leucht S, Lehert P, Soyka M (2008): Acamprosate supports abstinence, naltrexone prevents excessive drinking: evidence from a meta-analysis with unreported outcomes. J Psychopharmacol 22: 11–23.

    Article  PubMed  Google Scholar 

  • Royal College of Psychiatrists, British Psychological Society (2006): Schizophrenia. Full national clinical guideline on core interventions in primary and secondary care. Internet: www.guidance.nice.org.uk/CG1/guidance/pdf/English

  • Sass H, Soyka M, Mann K, Zieglgansberger W (1996): Relapse prevention by acamprosate. Results from a placebo-controlled study on alcohol dependence. Arch Gen Psychiatry 53: 673–680.

    Article  PubMed  CAS  Google Scholar 

  • Sayadipour A, Mago R, Kepler CK, Chambliss RB, Certa KM, Vaccaro AR, Albert TJ, Anderson DG (2012): Antidepressants and the risk of abnormal bleeding during spinal surgery: a case-control study. Eur Spine J 21: 2070–2078.

    Article  PubMed  Google Scholar 

  • Schubert I; Köster I, Lehmkuhl G (2010): Prävalenzentwicklung von hyperkinetischen Störungen und Methylphenidatverordnungen: Analyse der Versichertenstichprobe AOK Hessen/KV Hessen zwischen 2000 und 2007. Dtsch Arztebl Int 107: 615–621.

    PubMed  Google Scholar 

  • Schueler YB, Koesters M, Wieseler B, Grouven U, Kromp M, Kerekes MF, Kreis J, Kaiser T, Becker T, Weinmann S (2011): A systematic review of duloxetine and venlafaxine in major depression, including unpublished data. Acta Psychiatr Scand 123: 247–265.

    Article  PubMed  CAS  Google Scholar 

  • Siegmund-Schulze N (2012): Polypharmakotherapie im Alter: Weniger Medikamente sind oft mehr. Dtsch Ärztebl 109: A418–A420.

    Google Scholar 

  • Sikich L, Frazier JA, McClellan J, Findling RL, Vitiello B, Ritz L, Ambler D, Puglia M, Maloney AE, Michael E, De Jong S, Slifka K, Noyes N, Hlastala S, Pierson L, McNamara NK, Delporto-Bedoya D, Anderson R, Hamer RM, Lieberman JA (2008): Double-blind comparison of first- and second-generation antipsychotics in earlyonset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study. Am J Psychiatry 165: 1420–1431.

    Article  PubMed  Google Scholar 

  • Simon N (2011): Normal ist unnormal. Kritiker befürchten, dass in der Diagnostik-Bibel DSM Krankheiten geschaffen werden, die keine sind. Tagesspiegel 13.05.2011.

    Google Scholar 

  • Simon NM, Connor KM, LeBeau RT, Hoge EA, Worthington JJ 3rd, Zhang W, Davidson JR, Pollack MH (2008): Quetiapine augmentation of paroxetine CR for the treatment of refractory generalized anxiety disorder: preliminary findings. Psychopharmacology (Berl) 197: 675–681.

    Article  CAS  Google Scholar 

  • Smith D, Dempster C, Glanville J, Freemantle N, Anderson I (2002): Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis. Br J Psychiatry 180: 396–404.

    Article  PubMed  Google Scholar 

  • Sobanski E, Sabljic D, Alm B, Baehr C, Dittmann RW, Skopp G, Strohbeck-Kuehner P (2012): A randomized, waiting list-controlled 12-week trial of atomoxetine in adults with ADHD. Pharmacopsychiatry 45: 100–107.

    Article  PubMed  CAS  Google Scholar 

  • Spielmans GI (2008): Duloxetine does not relieve painful psychological symptoms in depression. A metaanalysis. Psychother Psychosom 77: 12–16.

    Article  PubMed  Google Scholar 

  • Spielmans GI, Berman MI, Linardatos E, Rosenlicht NZ, Perry A, Tsai AC (2013): Adjunctive atypical antipsychotic treatment for major depressive disorder: a meta-analysis of depression, quality of life, and safety outcomes. PLoS Med 10(3): e1001403.

    Article  PubMed  CAS  Google Scholar 

  • Sterke CS, Ziere G, van Beeck EF, Looman CW, van der Cammen TJ (2012): Dose-response relationship between selective serotonin re-uptake inhibitors and injurious falls: a study in nursing home residents with dementia. Br J Clin Pharmacol 73: 812–820.

    Article  PubMed  CAS  Google Scholar 

  • Stip E (2000): Novel antipsychotics: issues and controversies. Typicality of atypical neuroleptics. J Psychiatry Neurosci 25: 137–153.

    PubMed  CAS  Google Scholar 

  • Stroup TS, Lieberman JA, McEvoy JP, Swartz MS, Davis SM, Rosenheck RA, Perkins DO, Keefe RS, Davis CE, Severe J, Hsiao JK; CATIE Investigators (2006): Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatry 163: 611–622.

    Google Scholar 

  • Stübner S, Grohmann R, von Strahlendorff I, Rüther E, Möller HJ, Müller-Oerlinghausen B, Engel R, Horvarth A, Greil W (2010): Suicidality as a rare advserse event of antidepressant medication. Report from the AMSP Multicenter Drug Surveillance Project. J Clin Psychiatry 71: 1293–1307.

    Article  PubMed  Google Scholar 

  • Svensson S, Mansfield PR (2004): Escitalopram: superior to citalopram or a chiral chimera? Psychother Psychosom 73: 10–16.

    Article  PubMed  Google Scholar 

  • Swanson J, Greenhill L, Wigal T, Kollins S, Stehli A, Davies M, Chuang S, Vitiello B, Skrobala A, Posner K, Abikoff H, Oatis M, McCracken J, McGough J, Riddle M, Ghuman J, Cunningham C, Wigal S (2006): Stimulant-related reductions of growth rates in the PATS. J Am Acad Child Adolesc Psychiatry 45: 1304–1313.

    Article  PubMed  Google Scholar 

  • Swartz MS, Stroup TS, McEvoy JP, Davis SM, Rosenheck RA, Keefe RS, Hsiao JK, Lieberman JA (2008): What CATIE Found: Results From the Schizophrenia Trial. Psychiatr Serv 59: 500–506.

    Article  PubMed  Google Scholar 

  • Tandon R, Jibson MD (2003): Efficacy of newer generation antipsychotics in the treatment of schizophrenia. Psychoneuroendocrinology 28: 9–26.

    Article  PubMed  CAS  Google Scholar 

  • Taylor D, Paton C, Kapur Shitij (2009): Prescribing Guidelines. 10. Auflage. Informa healthcare.London.

    Google Scholar 

  • Thase ME (2003): Effectiveness of antidepressants: comparative remission rates. J Clin Psychiatry 64 (Suppl 2): 3–7.

    CAS  Google Scholar 

  • Thase ME, Entsuah R, Rudolph RL (2001): Remission rates during treatment with venlafaxine or selective reuptake inhibitors. Br J Psychiatry 178: 234–241.

    Article  PubMed  CAS  Google Scholar 

  • The BALANCE investigators and collaborators, Geddes JR, Goodwin GM, Rendell J, Azorin JM, Cipriani A, Ostacher MJ, Morriss R, Alder N, Juszczak E (2010): Lithium plus valproate combination therapy versus monotherapy for relapse prevention in bipolar I disorder (BALANCE): a randomised open-label trial. Lancet 375: 385–395.

    Google Scholar 

  • Tranulis C, Skalli L, Lalonde P, Nicole L, Stip E (2008): Benefits and risks of antipsychotic polypharmacy: an evidence-based review of the literature. Drug Saf 31: 7–20.

    Article  PubMed  CAS  Google Scholar 

  • Tsai AC, Rosenlicht NZ, Jureidini JN, Parry PI, Spielmans GI, Healy D (2011): Aripiprazole in the maintenance treatment of bipolar disorder: a critical review of the evidence and its dissemination into the scientific literature. PLoS Med 8: e1000434.

    Article  PubMed  CAS  Google Scholar 

  • Tsapakis EM, Gamie Z, Tran GT, Adshead S, Lampard A, Mantalaris A, Tsiridis E (2012): The adverse skeletal effects of selective serotonin reuptake inhibitors. Eur Psychiatry 27: 156–169.

    Article  PubMed  CAS  Google Scholar 

  • Turner EH, Matthews AM, Linardatos E, Tell RA, Rosenthal R (2008): Selective publication of antidepressant triuals and its influence on apparent efficacy. N Engl J Med 358: 252–260.

    Article  PubMed  CAS  Google Scholar 

  • Ujeyl M, Müller-Oerlinghausen B (2012): Antidepressiva zur Behandlung der Depression bei Palliativpatienten: Eine systematische Übersicht. Schmerz 26: 523–536 .

    Article  PubMed  CAS  Google Scholar 

  • Vitiello B, Correll C, van Zwieten-Boot B, Zuddas A, Parellada M, Arango C (2009): Antipsychotics in children and adolescents: increasing use, evidence for efficacy and safety concerns. Eur Neuropsychopharmacol 19: 629–635.

    Article  PubMed  CAS  Google Scholar 

  • Volz HP, Möller HJ, Reimann I, Stoll K (2000): Opipramol for the treatment of somatoform disorders. Results from a placebo-controlled trial. Eur Neuropsychopharmacol 10: 211–217.

    Article  PubMed  CAS  Google Scholar 

  • Walder A, Greil W, Baumann P (2009): Drug-induced Pisa syndrome under quetiapine. Prog Neuropsychopharmacol Biol Psychiatry 33: 1286–1287.

    Article  PubMed  CAS  Google Scholar 

  • Weinmann S, Read J, Aderhold V (2009): Influence of antipsychotics on mortality in schizophrenia: systematic review. Schizophr Res 113: 1–11.

    Article  PubMed  Google Scholar 

  • Whitaker R (2010): Anatomy of an epidemic. Magic bullets, psychiatric drugs, and the astonishing rise of mental illness in America. Crown Publishing, New York.

    Google Scholar 

  • Whittington CJ, Kendall T, Fonagy P, Cottrell D, Colgrove A, Boddington E (2004): Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data. Lancet 363: 1341–1345.

    Article  PubMed  CAS  Google Scholar 

  • Williams JWJr, Mulrow CD, Chiquette E, Hitchcock Noël P, Aguilar C, Cornell J (2000): Clinical guideline, part 2. A systematic review of newer pharmacotherapies for depression in adults: Evidence report summary. Ann Intern Med 132: 743–756.

    Article  PubMed  CAS  Google Scholar 

  • Wolter D (2009): Risiken von Antipsychotika im Alter speziell bei Demenzen. Eine Übersicht. Zschr. Gerontopsychologie u -psychiatrie 22: 17–56.

    Article  Google Scholar 

  • Zhou S, Chan E, Pan SQ, Huang M, Lee EJ (2004): Pharmacokinetic interactions of drugs with St John‘s wort. J Psychopharmacol 18: 262–276.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institut für Pharmakologie und Toxikologie, der Universität Würzburg, Würzburg, Versbacher Straße 9, 97078

    Prof. Dr. med. Martin J. Lohse

  2. Berlin, Bartningallee 11–13, 10555

    Prof. Dr. med. Bruno Müller-Oerlinghausen

Authors
  1. Prof. Dr. med. Martin J. Lohse
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Prof. Dr. med. Bruno Müller-Oerlinghausen
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Pharmakologisches Institut, der Universität Heidelberg, Im Neuenheimer Feld 366, 69120, Heidelberg

    Ulrich Schwabe

  2. AOK NORDWEST Die Gesundheitskasse, Edisonstraße 70, 24145, Kiel

    Dieter Paffrath

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer-Verlag Berlin, Heidelberg

About this chapter

Cite this chapter

Lohse, M.J., Müller-Oerlinghausen, B. (2013). Psychopharmaka. In: Schwabe, U., Paffrath, D. (eds) Arzneiverordnungs-Report 2013. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-37124-0_39

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-37124-0_39

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-37123-3

  • Online ISBN: 978-3-642-37124-0

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation